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Abstract
The parasite Trypanosoma cruzi causes Chagas disease, which remains a serious public health concern and continues to
victimize thousands of people, primarily in the poorest regions of Latin America. In the search for new therapeutic drugs
against T. cruzi, here we have evaluated both the in vitro and the in vivo activity of 5-hydroxy-3-methyl-5-phenyl-pyrazoline-
1-(S-benzyl dithiocarbazate) (H2bdtc) as a free compound or encapsulated into solid lipid nanoparticles (SLN); we compared
the results with those achieved by using the currently employed drug, benznidazole. H2bdtc encapsulated into solid lipid
nanoparticles (a) effectively reduced parasitemia in mice at concentrations 100 times lower than that normally employed for
benznidazole (clinically applied at a concentration of 400 mmol kg21 day21); (b) diminished inflammation and lesions of the
liver and heart; and (c) resulted in 100% survival of mice infected with T. cruzi. Therefore, H2bdtc is a potent trypanocidal
agent.
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Introduction
T. cruzi parasites are transmitted by insect vectors (triatomine
bugs). T.cruzi is the causative agent of Chagas disease, which is
silent and can remain asymptomatic for years [1], [2], [3]. A
century after its discovery, this disease remains a serious public
health issue—it is closely associated with human poverty and
political instability as well as with little investment in drug
development. According to the World Health Organization
(WHO), between seven and eight million people are infected
with T. cruzi worldwide, primarily in Latin America [4], [5],
[6]. One in every four Chagas patients develops a fatal
symptom of the disease due to lack of adequate diagnosis and
treatment.
Nifurtimox and benznidazole (BZN) are currently available to
treat the disease [7], [8], [9], [10]. However, neurological side
effects have led commercial nifurtimox production to be discon-
tinued [11]. As for BZN, although it is mainly effective during the
acute phase of the infection, it presents undesirable side effects
such as rash and gastrointestinal symptoms [12], so patients often
fail to comply with the treatment [8]. Long treatment periods (30,
60, or 90 days) and appropriate pediatric formulations not
available (administration of the medication to children often
requires tablet fractionation) also limit BZN use [9], [11], [13]. A
further concern is that no effective treatment for the symptomatic
chronic phase of Chagas disease exists, so the patients usually
receive palliative drugs at this stage [14], [15]. Therefore, a
number of researchers are making considerable efforts to find new
drugs to combat this disease.
Dithiocarbazates display notable biological and pharmacolog-
ical properties, including anticancer [16], [17], antimicrobial [17],
[18], [19], and insecticidal activities [20]. A recent study
has shown that cyclic compounds derived from S-dithiocarbazate
and 1,3-diketones exhibit significant trypanocidal activity [21]: in
particular, 5-hydroxy-3-methyl-5-phenyl-pyrazoline-1-(S-benzyl-
dithiocarbazate) (previously referred to as H2L
2a [21]) which
was renamed H2bdtc in this reference in this work (Figure 1)
constitutes a potential drug lead to develop a new agent
against the trypomastigote form of Tulahuen strains of T.
cruzi [21]. Nevertheless, the lipophilic character of H2bdtc
may limit its administration and result in low oral bioavailability
[22].
Drug delivery systems can help to circumvent this problem.
Because lipids have excellent physiological acceptability and can
promote drug absorption as well as selective lymphatic uptake,
researchers have focused on lipid-based drug release systems [23].
In particular, solid lipids constitute solid lipid nanoparticles (SLNs)
at room and body temperature. Since SLNs consist of biocom-
patible and biodegradable lipids with low or no human toxicity,
they can function as drug delivery systems [24], [25]. SLNs offer
many advantages: they protect the drug against degradation,
enable controlled drug release, and dismiss the use of organic
solvents. Moreover, SLNs can be produced on a large scale,
meeting industrial requirements [24], [26].
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Our group has used H2bdtc in vitro experiments involving the
Tulahuen strain (group I) [21]. The resistances of this group and of
the Y strain (group II) have been reported to be different, based on
phosphatase activities in T. cruzi homogenates [27]. Tulahuen
had an optimum phosphatase activity at pH 4.0 and the Y strain
at pH 7.0 [27]. Also in chronic phase has been associated with T.
cruzi II-restricted infections [28]. In this sense, evaluating the
trypanocidal activity of H2bdtc against the Y strain could support
the use of this compound as a new drug against T. cruzi. In
addition, so far little attention has been paid to the use of SLNs to
treat Chagas disease [29], [30]. Therefore, this work investigates
the in vitro and in vivo trypanocidal activity of free H2bdtc and
H2bdtc encapsulated into SLNs (H2bdtc-SLNs) against the Y
strain of T. cruzi and compares results with data obtained for the
currently available drug BZN.
Materials and Methods
General
BZN, a product manufactured by Lafepe, Brazil, was used as a
reference drug. The synthesis of H2bdtc has been described
previously [21]. RPMI Medium 1640 supplemented with 5%
bovine fetal serum (GIBCO, Grand Island, NY, USA), 100 IU
mL21 penicillin G, and 100 mg mL21 streptomycin (Gibco-BRL,
Grand Island, NY, USA) was employed. Dimethyl sulfoxide
(DMSO) and propidium iodide (PI) were obtained from Sigma-
Aldrich Chemicals Co. (St. Louis, MO, USA). Stearic acid and
sodium taurodeoxycholate were purchased from Sigma-Aldrich
(St. Louis, MO, USA), Lipoid S 100 (soya lecithin) was acquired
from Lipoid (Ludwigshafen, KOLN, Germany), and Amicon
Ultra 15, MWCO 100 K, was provided by Millipore (Billerica,
MA, USA).
Preparation of H2bdtc-loaded solid lipid nanoparticles
(H2bdtc-SLNs)
SLNs were prepared using a microemulsion method [31].
Briefly, the desired amount of sodium taurodeoxycholate (0.12%
w/v) was dissolved in hot aqueous phase, which was added to
melted stearic acid (0.95% w/v) containing soya lecithin (0.48%
w/v) and H2bdtc (0.02% w/v). The mixture was emulsified via
magnetic stirring at 90.062.0uC, until a thermodynamically stable
microemulsion formed. The SLNs dispersion was obtained by
cooling the hot microemulsion in cold water (2–5uC) under
vigorous stirring at 20,000 rpm for 10 min (IKA-T25
Ultra-turrax, Germany) at 1:20 ratio (microemulsion/cold water).
Next, the SLNs aqueous dispersion was subjected to high-pressure
homogenization (EmulsiFlex – C3, Germany) at 500 bars for
10 min.
Particle size, dispersity index (D-stroke), and zeta
potential determination
The particle size and dispersity of the H2bdtc-SLNs dispersion
were measured via photon correlation spectroscopy (PCS) [32];
the zeta potential was determined on the basis of the electropho-
resis mobility of the nanoparticles using the Zetasizer ZS Nano 90
(Malvern Instruments, UK.). The samples were diluted (1:10) with
distilled water at 25.0uC.
Atomic Force Microscopy (AFM)
The morphology of H2bdtc-SLNs was assessed using an atomic
force microscope (ICON Bruker, USA). The samples were
prepared by immersing freshly cleaved mica (Muscovite Mica
Substrates Sheets, SPI Supplies, China) in SLNs aqueous
dispersion and stored overnight, at room temperature, to complete
the drying process. The samples were evaluated by AFM in the
intermittent contact mode (tapping mode) by scanning the surface
of mica (2 mm62 mm in area) using a rectangular silicon cantilever
with a spring constant of 40 N m21 vibrating at a frequency of
320 kHz. Imaging was performed at room temperature, and the
topology image was used to determine the morphology of H2bdtc-
SLNs [33].
Drug entrapment efficiency (EE%) determination
The total H2bdtc content in the H2bdtc-SLNs was determined
by UV-vis spectroscopy at 400 nm (UV Spectrophotometer UV
1800, Shimadzu, Japan). First, a defined amount of H2bdtc-SLNs
was dissolved in dimethyl sulfoxide. The amount of encapsulated
drug was indirectly measured after centrifuging the H2bdtc-loaded
SLNs for 40 min at 6000 rpm (1605 G), at 25uC in a centrifuge
(Heraeus Megafuge 16 R Thermo Scientific, USA) equipped with
a membrane concentrator (Amicon Ultra 15, MWCO 100 K,
Millipore Corporation, USA). The filtrate was diluted with
dimethyl sulfoxide (1:1), and the concentration of free H2bdtc in
Figure 1. General molecular structure of the new cyclic S-
dithiocarbazate derivatives.
doi:10.1371/journal.pntd.0002847.g001
Author Summary
The protozoan parasite Trypanosoma cruzi causes Chagas
disease, a condition that affects the poorest regions of
Latin America mainly. The chronic phase of this disease
disables thousands of patients, constituting an important
public health issue. The pharmacotherapy that is currently
applied to treat the disease emerged many decades ago, is
ineffective in most patients, mainly during the chronic
phase, and has serious side effects. In a recent study, we
showed that the compound 5-hydroxy-3-methyl-5-phenyl-
pyrazoline-1-(S-benzyldithiocarbazate) (H2bdtc) is a poten-
tial drug candidate against the in vitro trypomastigote
form of Tulahuen strains of T. cruzi. Here we report that
H2bdtc loaded into solid lipid nanoparticles (H2bdtc-SLNs)
displays good trypanocidal activity against the trypomas-
tigote form of the Y strain of T. cruzi both in vitro and in
vivo. Our in vivo experiments revealed that H2bdtc-SLN is
100 times more active than benznidazole (BZN), the drug
that is commercially available to treat Chagas disease.
Surprisingly, this compound has no side effects on the T.
cruzi acute phase. Hence, we propose that H2bdtc-SLNs
possesses interesting anti-Trypanosoma properties.
Trypanocidal Activity H2bdtc in Nanoparticles
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the diluted filtrate was determined using the same conditions
employed to measure the total H2bdtc content used during the
loading procedure (section 2.2). The amount of H2bdtc loaded
into SLNs was calculated by subtracting the amount of free
H2bdtc in the filtrate from the total amount of H2bdtc used during
loading (26). EE (%) was determined using the following equation
[26], [34].
EE%~
drug loading
theoretical drug loading
x100
Partition coefficient of H2bdtc (K octanol/water)
Partition coefficients for the H2bdtc were determined in
triplicate in an n- octanol/water system following a published
procedure [35]. Measurements of H2bdtc n-octanol/water parti-
tion coefficients were carried out using the shake-flask method.
H2bdtc was dissolved in aqueous solution previously saturated with
n-octanol at a concentration of 1 mg/mL and mixed with the
same volume of octanol also previously saturated with water.
Samples were stirred for 30 min, separate in two phases, and
centrifugated for 10 min at 2000 rpm. The amount of H2bdtc in
the aqueous phase was quantified by UV-visible spectroscopy.
Mice
Female Swiss mice (6 to 8 weeks old) were bred and maintained
at the Department of Biochemistry and Immunology, School of
Medicine of Ribeirao Preto, University of Sa˜o Paulo, Ribeira˜o
Preto, Brazil. The mice were maintained in microisolator cages
under standard conditions; they were fed with food and water ad
libitum.
Ethics statement
All the in vivo procedures were performed in accordance with the
guidelines issued by the Brazilian College of Animal experimen-
tation (COBEA) and received prior approval by the Ethics
Committee on Animal Experimentation – CETEA (nu 006/2011)
of the School of Medicine of Ribeira˜o Preto.’’
Parasites and experimental infection
All the experiments were conducted using the trypomastigote
form of the Y strain of T. cruzi (Lineage type II). For the in vitro
experiments, parasites were grown in a fibroblast cell line (LLC-
MK2). For the in vivo experiments, mice were intraperitoneally
inoculated with 2.06103 bloodstream trypomastigote forms, which
had been derived from previously infected Swiss mice.
In vitro evaluation of the trypanocidal activity and
cytotoxicity of free H2bdtc and H2bdtc-loaded SLNs
The trypanocidal activities of free H2bdtc, H2bdtc-SLNs, and
BZN against the trypomastigote form of the T. cruzi Y strains were
evaluated as described previously [36]. To this end, the
trypomastigote culture at a concentration of 6.56106 parasites
mL21 was re-suspended in RPMI 1640 medium with 5% FBS.
Triplicate cultures were treated with one of the investigated drugs
and maintained at 37.060.1uC in a humidified atmosphere of 5%
CO2. To test parasite viability, the number of motile forms was
determined using a previously described method [37]. The
concentration of compound corresponding to 50% trypanocidal
activity after 24 h of incubation was expressed as the IC50try
(inhibitory concentration for the trypomastigote form).
Spleen cells isolated from C57BL/6 mice, macerated in RPMI
1640 medium (Gibco), and filtered using a 100-mm pore filter were
used to evaluate the cytotoxicity in vitro. The isolated cells were
centrifuged at 1500 rpm for 10 min, and erythrocytes were lysed
in lysis buffer for 5 min, at room temperature. Cells were washed,
counted, and resuspended at 6.56106 mL21 in RPMI medium
containing 5% fetal bovine serum. The spleen cells were seeded to
a 96-well microplate (n = 2) and incubated for 24 h with H2bdtc
diluted in dimethyl sulfoxide (DMSO, final H2bdtc concentration
not exceeding 0.5%) or H2bdtc-SLNs (concentrations ranging
from 125 mM to 0.24 mM in serial dilutions). BZN (Roche) was
used as the reference drug; Tween 20 was employed as positive
control for cell death. After the incubation period, the cells were
washed and incubated with propidium iodide at a final concen-
tration of 10 mg mL21. Cell cytotoxicity was measured on a flow
cytometer (FACSCantoII - BD), and the data were analyzed using
the FlowJo program (Tree Star).
In vivo evaluation of the cytotoxicity and trypanocidal
activity of free H2bdtc and H2bdtc-SLNs
Female Swiss mice aged between 6 and 8 weeks, weighing
between 20 and 25 g, were infected with 2.06103 blood
trypomastigotes per animal. A total of four experimental groups
consisting of seven Swiss mice each were included in the study.
Treatment started at day 5 post-inoculation (p.i.). BZN, free
H2bdtc and H2bdtc-SLNs were orally administered at 4 mmol
kg21 (BZN 1.0 mg kg21 day-1/free H2bdtc and H2bdtc-SLNs
1.4 mg kg21 day21) per day for 10 consecutive days. The
following treatments were applied: Group 1 = PBS control group;
infected and not treated, Group 2 = infected and treated with
BZN, Group 3 = infected and treated with free H2bdtc, and
Group 4 = infected and treated with H2bdtc-SLNs. To evaluate
parasitaemia and mortality, seven animals from each group were
used. Seven animals were killed at day 22 p.i. (early mortality), to
quantify inflammation of the heart and liver and to measure
creatine kinase-MB (CK-MB) and glutamic-pyruvic transaminase
(GPT) production.
Parasitemia and mortality
Parasitemia was analyzed on alternate days from day 7 p.i.; to
this end, 5 mL of fresh blood was collected from the animal tail.
The count of 100 fields was performed via direct observation
under a light microscope [38]. Mortality was inspected on a daily
basis until day 60.
Histological analysis
Groups of seven mice were euthanized at day 20 p.i., and
portions of the heart and liver were fixed in paraffin for
histological analysis. To assess inflammatory infiltration via light
microscopy DP71 (Olympus Optical Co, Japan), tissues were
sectioned at a 5-mm thickness and stained with hematoxylin-eosin
(H&E). Each tissue section was imaged 25 times, and the
percentage of the area occupied by cellular infiltrates was
determined using the Image J program.
Quantitative real-time PCR (qPCR)
Quantitative PCR was used to determine the amount of
parasitic DNA in heart tissues. Briefly, DNA was purified from
25 mg of heart tissue using a QIAamp DNA Mini Kit (Qiagen),
according to the manufacturer’s instructions. Each PCR reaction
comprised 40 ng of genomic DNA; 0.3 mM of the T. cruzi-specific
primers TCZ-F 59-GCTCTTGCCCACAMGGGTGC-39 (M = A
or C) TCZ-R 59-CCAAGCAGCGGATAGTTCAGG-39 [39],
Trypanocidal Activity H2bdtc in Nanoparticles
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which amplify a 182-bp product; 7.65 mL of GoTaq qPCR Master
Mix; and H2O (final total volume of 15 mL).
The reactions were performed using the Real-Time PCR System.
The cycling program involved a denaturation cycle of 95.0uC for
10 min, followed by 40 cycles of the three steps of the amplification
phase: 95.0uC for 15 s, 55.0uC for 30 s, and 72.0uC for 15 s. The
melting phase was performed at 95.0uC for 15 s and at 60.0uC for
1 min, followed by a 0.3uC ramp and then 95.0uC for 15 s. During
the melting phase, the acquisition setting was set at step. The data
were analyzed with StepOne Software version 2.2.2.
Serum activity of creatine kinase isoform MB (CK-MB) and
glutamic-pyruvic transaminase (GPT)
The cardiac and hepatic lesions of mice infected with T. cruzi,
treated or not, were assessed by measuring the creatine kinase-MB
(CK-MB) and glutamic-pyruvic transaminase (GPT) levels,
respectively, in the serum at day 22 p.i. The CK-MB levels were
measured using a CK-MB kit (Liquiform, Brazil), as previously
described [40]. Absorbance was measured on a microplate
spectrophotometer (EMAX Molecular Devices Corporation,
California, EUA). The color produced from this reaction was
measured at a wavelength of 340 nm; the results are expressed in
U/I. GPT was analyzed using an ALT/GPT kit (Liquiform,
Brazil), according to the manufacturer’s instructions. The color-
imetric assay determines the amount of pyruvate produced
according to the Reitman and Frankel method, from the
formation of 2,4-dinitrophenylhydrazine [41]. The color produced
by this reaction was measured at a wavelength of 505 nm.
Statistical analyses
Data are expressed as the mean SEM. Student’s t-test was used
to analyze the statistical significance of the variation between the
infected and control assays. Differences were considered statisti-
cally significant when P,0.05. The differences in droplet size,
dispersity, zeta potential, and entrapment efficiency values
achieved during the stability test were evaluated via a one-way
ANOVA analysis of variance followed by Tukey post-test analysis.
The differences were considered statistically significant when P,
0.05. All the analyses were performed using PRISM 5.0 software
(Graph Pad, San Diego, CA, US).
Results
Preparation and characterization of H2bdtc-SLNs
The H2bdtc showed a lipophilic character (Log P (o/w)
= 2.6960.03) and were efficiently encapsulated in this manner in
SLNs. On the basis of Photon Correlation Spectroscopy (PCS),
H2bdtc-SLNs had diameter of 127.4610.2 nm and dispersity
lower than 0.3; the zeta potential revealed a negative surface
charge (256.164.4 mV) (Table 1). The entrapment efficiency was
98.1661.12, showing that the drug dispersed well within the
lipid matrix. Atomic force microscopy images revealed that
Table 1. Particle size, zeta potential, dispersity index and entrapment efficiency of SLNs (mean 6 SD, n = 3).
Formulation
Compounds Mean Particle (nm) D-Stroke Zeta Potential (mV) Entrapment Efficiency (%)
SLN 132.3610.2 0.26060.0098 260.2062.30 98.1661.12
H2bdtc-SLN 127.460.130 0.22960.130 256.1064.40
*Dispersity (D-stroke). SLNs: SLNs without drug loaded and H2bdtc loaded in SLNs: H2bdtc loaded in SLNs.
doi:10.1371/journal.pntd.0002847.t001
Figure 2. Atomic Force Microscopy micrographs of H2bdtc loaded in SLNs (A) 2 mm62 mm three-dimensional image. (B) 2 mm62 mm
planar image.
doi:10.1371/journal.pntd.0002847.g002
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H2bdtc-SLNs particles were spherical, with an average diameter
of approximately 180 nm (Figure 2), agreeing with the PCS
results.
In vitro evaluation of the trypanocidal activity and
cytotoxicity of free H2bdtc and H2bdtc- SLNs
We assessed the in vitro trypanocidal activity of free H2bdtc,
H2bdtc-SLNs and BZN after 24 h of incubation with T. cruzi
trypomastigotes forms. Free H2bdtc presents IC50try (inhibitory
concentrations against bloodstream trypomastigote) as 0.5060.12,
H2bdtc-SLNs as 1.8360.18 and BZN 0.5060.39 mM (Figure 3A).
We also measured the cytotoxicity of free H2bdtc and H2bdtc-
SLNs in spleen cells of Swiss mice; none of the tested drugs was
significantly cytotoxic (Figure 3B). Hence, both free H2bdtc and
H2bdtc-SLNs displayed similar in vitro trypanocidal activity to
BZN; this activity was not associated with general cytotoxicity but
rather with specific activity against the parasite.
In vivo activity of free H2bdtc and H2bdtc-SLNs
We performed in vivo experiments to investigate the controlled
release behavior of H2bdtc from H2bdtc-SLNs; we also compared
the activities of free H2bdtc and H2bdtc-SLNs against T. cruzi. We
decided to use an H2bdtc-SLNs concentration of 4 mmol kg
21
day21. During the in vivo treatments on the basis of preliminary in
vivo results obtained for the Y strain of T. cruzi, which revealed that
H2bdtc had low level of parasitemia (Supporting Information:
Figure S1). In all the infected groups, parasitemia peaked at day
9 p.i., with gradual parasite elimination from the bloodstream
after day 11 p.i. It is worth noting that we employed BZN
concentrations 100 times lower than that used for Chagas patients.
H2bdtc-SLNs eliminated 70% of the circulating parasites at the
peak of infection, whereas free H2bdtc and the positive control
BZN eliminated 48 and 15% of the parasites, respectively, as
compared with the control group treated with PBS (Figure 4A). In
agreement with the data revealing reduced parasitemia, mice
treated with H2bdtc-SLNs presented 100% survival rate
(Figure 4B), similar to the result achieved with BZN administered
at a clinical dose of 400 mmol kg21 day21 (100 times more
concentrated than the concentration used herein). Compared with
the control group (PBS), groups treated with free H2bdtc and BZN
exhibited a survival rate of 57%.
Cardiac and liver lesions
Encouraged by the in vivo results, we evaluated how free H2bdtc,
H2bdtc-SLNs, and BZN affected the cardiac and hepatic tissues of
the surviving animals. Infected mice treated with H2bdtc-SLNs
presented reduced cardiac inflammation (Figure 5A) and heart
lesions were absent (Figure 5B), as established by the absence of
CK-MB, the enzyme released into plasma during cardiac lesion.
Figure 3. In vitro evaluation of the trypanocidal activity and cytotoxicity of H2bdtc – (concentrations range from 125 mM to 0.24 mM
in serial dilutions). (A) Percentage of trypanocidal activity of free H2bdtc and H2bdtc loaded in SLNs against the Y strain of T. cruzi analyzed by
quantifying viable parasites via microscopy after 24 h post-treatment. (B) Percentage of cytotoxicity of free H2bdtc and H2bdtc loaded in SLNs in
spleen cells derived from mice after 24 h via propidium iodide treatment and FACS analysis. The mean + SEM is shown and is representative of three
independent experiments (n = 2). Statistically significant differences compared with the control (BZN). Anova, Bonferroni post - test: ***p,0.001
doi:10.1371/journal.pntd.0002847.g003
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Treatment with free H2bdtc diminished cardiac damage by 50%
as compared with therapies with BZN or PBS. Concerning the
ability of the tested compounds to reduce the liver damage caused
by the parasite, H2bdtc-SLNs decreased inflammatory infiltration
in the liver and hepatic toxicity more effectively, as assessed by
measuring the glutamic-pyruvic transaminase (GTP) levels in the
Figure 4. Parasitaemia and survival rates of mice infected with T. cruzi and treated with free H2bdtc, H2bdtc encapsulated in SLNs
and BZN. (A) Parasitaemia was monitored on days 7, 9, 11 and 13 after infection. (B) Survival was monitored daily for 60 consecutive days. The mean
+ SEM is shown and is representative of three independent experiments (n = 7). Statistically significant differences compared with the control (BZN). T
student test: ***p,0.001
doi:10.1371/journal.pntd.0002847.g004
Figure 5. Cardiac and liver lesions of T. cruzi- infected animals after treatment with H2bdtc encapsulated in solid lipid
nanoparticles. (A) Quantification of cellular nuclei per 50 mm2 of heart tissues derived from non-treated and treated animals. (B) Quantification of
CK-MB in the serum of infected and treated mice. (C) Quantification of cellular nuclei per 50 mm2 of liver tissues derived from non-treated and treated
animals. (D) Quantification of glutamic-pyruvic transaminase (GPT) levels. The mean + statistically significant differences compared with the control
are denoted by: *p,0.05, **p,0.01 e ***p,0.001, T student test.
doi:10.1371/journal.pntd.0002847.g005
Trypanocidal Activity H2bdtc in Nanoparticles
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serum (Figure 5C, 5D). Considering all these results, it is possible
to infer that treatment with H2bdtc per se reduced exacerbation of
the inflammatory response on T. cruzi target organs and,
consequently, tissue damage. Loading of H2bdtc into nanoparti-
cles afforded even better results, producing no lesion in the heart
tissue.
Because it is well established that parasites play an important
role in cardiac damage during T. cruzi infection [42], [43], we
quantified T. cruzi DNA derived from the heart tissues of mice
treated with the tested compounds via real-time PCR. Treatment
with H2bdtc-SLNs reduced the parasite burden significantly more
effectively as compared with the other tested drugs (Figure 6),
indicating that killing the parasites is most likely the mechanism
through which H2bdtc-SLNs acts to diminish tissue lesions and
enhance mice survival.
Discussion
Chagas disease has often been pointed out as being a major
neglected disease; the drugs that are currently available to treat
this disease are little effective [5], [12]. Efforts have been made to
provide the affected populations with new compounds to treat the
disease. In the past few years, researchers have tested many
substances against T. cruzi. In particular, H2bdtc, which belongs to
the class of S-dithiocarbazates, is efficient against the parasite [21].
A 24-h UV-vis study into the stability of H2bdtc in aqueous solution
did not evidence any changes in the spectrum of this compound.
Nevertheless, this drug is poorly soluble in water (1.5061026 M),
which has limited its use to treat Chagas disease. Because H2bdtc is
lipophilic (Log P(o/w) = 2,6960,03) and SLNs constitute effective
oral drug delivery systems, we loaded H2bdtc into this type of lipid.
We prepared the SLNs by the microemulsion method [31],
[44], to avoid the use of organic solvents. The resulting SLNs had
diameter of approximately 120 nm, dispersity lower than 0.3, and
spherical shape, which made these lipids suitable for oral
administration [45], [46], [47], [48]. The zeta potential measure-
ment allowed us to predict the stability of the colloidal dispersion.
Charged particles have high zeta potential–negative or positive–
and usually do not aggregate [49]. The zeta potential results
revealed that the SNPs prepared here had a negative surface
charge (256.164.4 mV), indicating that the system was physically
stable. Loaded and unloaded SNPs had similar zeta potentials,
attesting that the tested drug was completely and uniformly
dispersed inside the lipid matrix [50].
Encapsulation did not change the in vitro trypanocidal activity of
H2bdtc, which was higher than the activity of BZN at the same
concentration used here. The IC50 values obtained for H2bdtc against
the trypomastigote form of the Y strain of T. cruzi were comparable
with or superior to those of previously reported active compounds
[51], [52]. Other papers have also described the use of colloidal drug
carriers such as liposomes and nanoparticles to treat Chagas diseases
[53], [54]. Treatment of T. cruzi infection with a BZN-loaded
liposome increased BZN levels in the liver and blood. Intravenous
administration of free BZN and BZN-encapsulated liposome at
0.2 mg of BZN per kilogram of body weight revealed three-fold higher
BZN accumulation in the liver in the second case. Nevertheless,
encapsulation failed to improve the in vivo BZN efficacy [55].
Liposome instability prevents their use as drug delivery systems
[56]. Fortunately, we verified that free H2bdtc and H2bdtc-SLNs
were not toxic to the spleen cells of Swiss mice, which encouraged
us to directly test the effect of H2bdtc formulations in vivo using a
murine model of acute Chagas disease.
Treatment started with a relatively low oral dose of free H2bdtc
and H2bdtc-SLNs (4 mmol kg
21 day21) as compared with
currently employed doses of the commercially available BZN
and compounds tested in the literature [57], [58]. H2bdtc-SLNs,
Free H2bdtc and BZN reduced the presence of parasites in the
blood of infected mice in 70, 48 and 15% respectively. H2bdtc-
SLNs maintained 100% survival rate of infected mice, whereas
43% of the mice treated with free H2bdtc or BZN at the same
concentration succumbed to the disease. It is noteworthy that free
SLN and PBS elicited similar levels of parasitemia (Supporting
Information: Figure S2). Therefore, the use of SLNs as a drug
delivery system increased the oral bioavailability of the target drug,
as previously described [59], [60], [61], [62], [63]. H2bdtc loading
into SLNs overcame the problems inherent to the poor water
solubility of the compound and may be could make it more
accessible to the parasite (however, detailed pharmacokinetic data
will be presented in a separate forthcoming paper). Additionally,
some authors have proposed that drugs loaded into SLNs
measuring 20–500 nm are absorbed by lymphatic transport,
which reduces the first-pass metabolism [62], [63].
Analysis of histological sections of liver and heart tissues
(Supporting Information: Figure: Figure S3 and Figure S4)
revealed that the inflammatory infiltrate decreased in all the
treated groups as compared with the control. The reduction was
more pronounced in mice treated with H2bdtc-SLNs, possibly
because parasitemia was lower in this case. This corroborated with
findings from previous studies [64], [65] and confirmed that the
parasite elicited intense inflammation especially in the cardiac
tissues. The fact that the heart tissues of mice treated with H2bdtc-
SLNs were perfectly preserved agreed with the notion that the
presence of inflammatory infiltrates is associated with cardiac
tissue damage [66], [67] and also with parasitic load [42], [43].
Indeed, mice treated with H2bdtc-SLNs exhibited significantly
lower parasite burden as compared with the other groups. Hence,
the reduced parasitism elicited by H2bdtc-SLNs helps to preserve
the heart tissues of mice infected with T. cruzi, allowing us to
conclude that H2bdtc is a potent trypanocidal agent.
Figure 6. Quantification of the parasites load in cardiac tissues
via real-time PCR. The presence of T. cruzi in infected heart tissue
mice were analyzed by PCR 22days after infection. Statistically
significant differences were showed in the figure.
doi:10.1371/journal.pntd.0002847.g006
Trypanocidal Activity H2bdtc in Nanoparticles
PLOS Neglected Tropical Diseases | www.plosntds.org 7 May 2014 | Volume 8 | Issue 5 | e2847
Investigation into how H2bdtc interacts with possible targets
represents a theme for future studies. For the time being, we must
bear in mind that triazoles and thiosemicarbazones are well known
for inhibiting cruzain, a protein belonging to the family of cysteine
proteases and which is the most abundant protein in T. cruzi.
Cruzain is essential for parasite development and survival within
host cells [68]. H2bdtc bears pyrazole and dithiocarbazate parts,
which are similar to triazoles and thiosemicarbazones, respective-
ly, and could account for its trypanocidal action.
A mechanism of action similar to that of BZN probably does not
occur. The BZN mode of action involves intracellular reduction of
the nitro group, to produce highly reactive free radicals and/or
electrophilic metabolites that could affect other systems, especially
host systems, contributing to the cytotoxic effects observed in
BZN-treated patients [69].
It is worth noting that cysteine proteases are very important for
parasites; however, the lack of redundancy with respect to their
mammalian hosts makes these proteases interesting targets for the
development of new therapeutic agents [70]. Altogether, our
findings show that H2bdtc-SLNs are a possible drug candidate to
treat Chagas disease: it is more efficient against T. cruzi than the
drugs used in current therapies.
Supporting Information
Figure S1 In vivo evaluations of the trypanocidal activity free-H2bdtc
and H2bdtc-SLNs – (concentrations 4 mM, 40 mM and 80 mM) (
_____)
Parasitaemia rate of mice infected with T. cruzi and treated with free-
H2bdtc. (----) Parasitaemia rate of mice infected with T. cruzi and
treated with H2bdtc encapsulated in solid lipid nanoparticles.
Parasitaemia was monitored on days 7, 9, 11 and 13 after infection.
The mean + SEM is shown and is representative of three independent
experiments (n = 7). Statistically significant differences compared with
the free-H2bdtc. T student test: **p,0.01 and ***p,0.001.
(TIF)
Figure S2 Parasitaemia of mice infected with T. cruzi and
treated with free SLNs and PBS. Parasitaemia was monitored on
days 7, 9, 11 and 13 after infection.
(TIF)
Figure S3 Cardiac lesions of T. cruzi-infected animals after
treatment with H2bdtc encapsulated in SLNs. The sections
represent of heart tissues inflammatory process composed of
various cell types (21 days after infection).
(TIF)
Figure S4 Liver lesions of T. cruzi-infected animals after
treatment with H2bdtc encapsulated in SLNs. The sections
represent of liver tissues inflammatory process composed of
various cell types (21 days after infection).
(TIF)
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